Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267535 | 0.83 | CXCR3 (0.41) | TAS2R14CXCR3LSS | |
| SCHEMBL1240985 | 0.83 | PYCR1 (0.51) | PYCR1CXCR3LSS | |
| SCHEMBL17887960 | 0.83 | PYCR1 (0.51) | PYCR1TAS2R14CXCR3SLC6A2SLC6A4 | |
| SCHEMBL14045705 | 0.82 | ALDH1A1 (0.52) | PYCR1 | |
| SCHEMBL22794600 | 0.81 | SLC6A2 (0.39) | PYCR1SLC6A2SLC6A4LSS | |
| SCHEMBL12891100 | 0.80 | EP300 (0.47) | PYCR1CXCR3SLC6A2SLC6A4LSS | |
| SCHEMBL26668497 | 0.79 | EP300 (0.46) | CXCR3SLC6A2SLC6A4LSS | |
| SCHEMBL16312619 | 0.79 | PYCR1 (0.65) | PYCR1NPSR1 | |
| SCHEMBL8283980 | 0.77 | ALDH1A1 (0.46) | PYCR1 | |
| SCHEMBL4686478 | 0.75 | CARM1 (0.47) | PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | PYCR1 258/4885TAS2R14 2862/4885CXCR3 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.